

# Updated (2023–2024 Formula) COVID-19 Vaccine

Interim 2023–2024 COVID-19 Immunization Schedule  
for Persons 6 Months of Age and Older



**Table 1b.** For people who are **NOT** moderately or severely immunocompromised\*

## 2023–24 Pfizer-BioNTech COVID-19 Vaccine

Vaccine type: mRNA - Do **NOT** use any previously available Pfizer-BioNTech COVID-19 vaccine products.

Age	COVID-19 Vaccination History <sup>†</sup> (regardless of COVID-19 vaccine formula)	2023–24 Vaccine Schedule	Administer
<b>6 months through 4 years</b>	Unvaccinated (0 doses)	Give a 3-dose initial series. Administer: <ul style="list-style-type: none"> <li>• Dose 1 now</li> <li>• Dose 2 at least 3–8 weeks after Dose 1<sup>‡</sup></li> <li>• Dose 3 at least 8 weeks (2 months) after Dose 2</li> </ul>	0.3 mL/3 $\mu$ g From yellow-capped vial with yellow label Intramuscular (IM) injection
	1 previous dose of any Pfizer-BioNTech COVID-19 Vaccine (Dose 1) <sup>§</sup>	Complete series. Administer: <ul style="list-style-type: none"> <li>• Dose 2 at least 3–8 weeks after Dose 1<sup>‡</sup></li> <li>• Dose 3 at least 8 weeks (2 months) after Dose 2</li> </ul>	
	2 doses of any Pfizer-BioNTech COVID-19 Vaccine (Doses 1 and 2) <sup>¶</sup>	Complete series. Administer: <ul style="list-style-type: none"> <li>• Dose 3 at least 8 weeks (2 months) after Dose 2</li> </ul>	
	3 or more doses Pfizer-BioNTech COVID-19 Vaccine, <b>NOT</b> including at least 1 dose of 2023–24 COVID-19 vaccine <sup>§</sup>	Give 1 dose at least 8 weeks (2 months) after the last dose	
	3 or more doses Pfizer-BioNTech COVID-19 Vaccine, <b>INCLUDING</b> at least 1 dose of 2023–24 COVID-19 vaccine <sup>§</sup>	No further doses are indicated	
<b>5 through 11 years</b>	Unvaccinated (0 doses)	Give 1 dose now	0.3 mL/10 $\mu$ g From blue-capped vial with blue label Intramuscular (IM) injection
	Any number of previous doses COVID-19 vaccine, <b>NOT</b> including at least 1 dose of 2023–24 COVID-19 vaccine	Give 1 dose at least 8 weeks (2 months) after the last dose	
	Any number of previous doses COVID-19 vaccine, <b>INCLUDING</b> at least 1 dose of 2023–24 COVID-19 vaccine	No further doses are indicated	
<b>12 years and older</b>	Unvaccinated (0 doses)	Give 1 dose now	0.3 mL/30 $\mu$ g From gray-capped vial with gray label or manufacturer-filled syringe with gray box on label Intramuscular (IM) injection
	Any number of previous doses COVID-19 vaccine, <b>NOT</b> including at least 1 dose of 2023–24 COVID-19 vaccine	Give 1 dose at least 8 weeks (2 months) after the last dose	
	Any number of previous doses COVID-19 vaccine, <b>INCLUDING</b> at least 1 dose of 2023–24 COVID-19 vaccine	No further doses are indicated	

\* Persons with a recent SARS-CoV-2 infection may consider delaying vaccination by 3 months from symptom onset or positive test (if infection was asymptomatic).

† COVID-19 vaccination history refers to previous receipt of dose(s) of original monovalent (ancestral) mRNA, bivalent mRNA vaccine, Updated (2023–2024 Formula), or a combination of the three, unless otherwise specified.

‡ An 8-week interval between the first and second COVID-19 vaccine (Moderna, Novavax, and Pfizer-BioNTech) doses might be optimal for some people as it might reduce the small risk of myocarditis and pericarditis associated with these vaccines.

§ People who are recommended to receive a multidose mRNA series for initial vaccination (i.e., children ages 6 months–4 years and people who are moderately or severely immunocompromised) should receive all doses from the same manufacturer. However, in the following exceptional situations a different age-appropriate COVID-19 vaccine product may be administered: the same vaccine is not available, the person would otherwise not complete the vaccination series, or the person starts but is unable to complete a vaccination series with the same vaccine due to a contraindication.

¶ For children who have received 1 Moderna and 1 Pfizer-BioNTech vaccines of any formulation, follow a 3-dose schedule. A third dose of either Moderna vaccine or Pfizer-BioNTech vaccine should be administered at least 8 weeks after the second dose.

# Updated (2023–2024 Formula) COVID-19 Vaccine

Interim 2023–2024 COVID-19 Immunization Schedule  
for Persons 6 Months of Age and Older



**Table 2b.** For people who **ARE** moderately or severely immunocompromised

## 2023–24 Pfizer-BioNTech COVID-19 Vaccine

Vaccine type: mRNA - Do **NOT** use any previously available Pfizer-BioNTech COVID-19 vaccine products.

Age	COVID-19 Vaccination History* (regardless of COVID-19 vaccine formula)	2023–24 Vaccine Schedule	Administer
<b>6 months through 4 years</b>	Unvaccinated: (0 doses)	Give a 3-dose initial series. Administer: <ul style="list-style-type: none"> <li>• Dose 1 now</li> <li>• Dose 2 at least 3 weeks after Dose 1</li> <li>• Dose 3 at least 8 weeks (2 months) after Dose 2</li> </ul>	0.3 mL/3 $\mu$ g  From yellow-capped vial with yellow label  Intramuscular (IM) injection
	1 previous dose of any Pfizer-BioNTech COVID-19 Vaccine (Dose 1) <sup>†</sup>	Complete series. Administer: <ul style="list-style-type: none"> <li>• Dose 2 at least 3 weeks after Dose 1</li> <li>• Dose 3 at least 8 weeks (2 months) after Dose 2</li> </ul>	
	2 doses of any Pfizer-BioNTech COVID-19 Vaccine (Doses 1 and 2) <sup>††</sup>	Complete series. Administer: <ul style="list-style-type: none"> <li>• Dose 3 at least 8 weeks (2 months) after Dose 2</li> </ul>	
	3 or more doses of Pfizer-BioNTech COVID-19 Vaccine, <b>NOT</b> including at least 1 dose of 2023–24 COVID-19 vaccine <sup>†</sup>	Give 1 dose at least 8 weeks (2 months) after the previous dose	
	3 or more doses of Pfizer-BioNTech COVID-19 Vaccine, <b>INCLUDING</b> at least 1 dose of 2023–24 COVID-19 vaccine <sup>†</sup>	People who are moderately or severely immunocompromised have the <b>option to receive 1 additional dose at least 8 weeks (2 months) following</b> the last recommended dose. Further additional dose(s) may be administered, <b>informed by the clinical judgement</b> of a healthcare provider and personal preference and circumstances. Any further additional doses should be administered at <b>least 8 weeks (2 months) after the last COVID-19 vaccine dose.</b>	
<b>5 through 11 years</b>	Unvaccinated: (0 doses)	Give a 3-dose initial series. Administer: <ul style="list-style-type: none"> <li>• Dose 1 now</li> <li>• Dose 2 at least 3 weeks after Dose 1</li> <li>• Dose 3 at least 4 weeks after Dose 2</li> </ul>	0.3 mL/10 $\mu$ g  From blue-capped vial with blue label  Intramuscular (IM) injection
	1 previous dose of any Pfizer-BioNTech COVID-19 Vaccine (Dose 1) <sup>†</sup>	Complete series. Administer: <ul style="list-style-type: none"> <li>• Dose 2 at least 3 weeks after Dose 1</li> <li>• Dose 3 at least 4 weeks after Dose 2</li> </ul>	
	2 doses of any Pfizer-BioNTech COVID-19 Vaccine (Doses 1 and 2) <sup>†</sup>	Complete series. Administer: <ul style="list-style-type: none"> <li>• Dose 3 at least 4 weeks after Dose 2</li> </ul>	
	3 or more doses of Pfizer-BioNTech COVID-19 Vaccine, <b>NOT</b> including at least 1 dose of 2023–24 COVID-19 vaccine <sup>†</sup>	Give 1 dose at least 8 weeks (2 months) after the last dose	
	3 or more doses of Pfizer-BioNTech COVID-19 Vaccine, <b>INCLUDING</b> at least 1 dose of 2023–24 COVID-19 vaccine <sup>†</sup>	People who are moderately or severely immunocompromised have the <b>option to receive 1 additional dose at least 8 weeks (2 months) following</b> the last recommended dose. Further additional dose(s) may be administered, <b>informed by the clinical judgement</b> of a healthcare provider and personal preference and circumstances. Any further additional doses should be administered at <b>least 8 weeks (2 months) after the last COVID-19 vaccine dose.</b>	

\* COVID-19 vaccination history refers to previous receipt of dose(s) of original monovalent (ancestral) mRNA, bivalent mRNA vaccine, Updated (2023–2024 Formula), or a combination of the three, unless otherwise specified.

<sup>†</sup> People who are recommended to receive a multidose mRNA series for initial vaccination (i.e., children ages 6 months–4 years and people who are moderately or severely immunocompromised) should receive all doses from the same manufacturer. However, in the following exceptional situations a different age-appropriate COVID-19 vaccine product may be administered: the same vaccine is not available, the person would otherwise not complete the vaccination series, or the person starts but is unable to complete a vaccination series with the same vaccine due to a contraindication.

<sup>‡</sup> For children who have received 1 Moderna and 1 Pfizer-BioNTech vaccines of any formulation, follow a 3-dose schedule. A third dose of either Pfizer-BioNTech vaccine or Pfizer-BioNTech vaccine should be administered at least 8 weeks after the second dose.

# Updated (2023–2024 Formula) COVID-19 Vaccine

Interim 2023-2024 COVID-19 Immunization Schedule  
for Persons 6 Months of Age and Older



**Table 2b.** For people who **ARE** moderately or severely immunocompromised *Continued*

2023-24 Pfizer-BioNTech COVID-19 Vaccine - CONTINUED			
Vaccine type: mRNA - Do <b>NOT</b> use any previously available Pfizer-BioNTech COVID-19 vaccine products.			
Age	COVID-19 Vaccination History* (regardless of COVID-19 vaccine formula)	2023-24 Vaccine Schedule	Administer
12 years and older	Unvaccinated: 0 doses	Give a 3-dose initial series. Administer: <ul style="list-style-type: none"> <li>• Dose 1 now</li> <li>• Dose 2 at least 3 weeks after Dose 1</li> <li>• Dose 3 at least 4 weeks after Dose 2</li> </ul>	0.3 mL/30 µg  From gray-capped vial with gray label or manufacturer-filled syringe with gray box on label  Intramuscular (IM) injection
	1 previous dose of any Pfizer-BioNTech COVID-19 Vaccine (Dose 1) <sup>†</sup>	Complete series. Administer: <ul style="list-style-type: none"> <li>• Dose 2 at least 3 weeks after Dose 1</li> <li>• Dose 3 at least 4 weeks after Dose 2</li> </ul>	
	2 doses of any Pfizer-BioNTech COVID-19 Vaccine (Doses 1 and 2) <sup>†</sup>	Complete series. Administer: <ul style="list-style-type: none"> <li>• Dose 3 at least 4 weeks after Dose 2</li> </ul>	
	3 or more doses of Pfizer-BioNTech COVID-19 Vaccine, <b>NOT</b> including at least 1 dose of 2023–24 COVID-19 vaccine <sup>†</sup>	Give 1 dose at least 8 weeks (2 months) after the last dose	
	3 or more doses of Pfizer-BioNTech COVID-19 Vaccine, <b>INCLUDING</b> at least 1 dose of 2023–24 COVID-19 vaccine <sup>†</sup>	People who are moderately or severely immunocompromised have the <b>option to receive 1 additional dose at least 8 weeks (2 months) following</b> the last recommended dose. Further additional dose(s) may be administered, <b>informed by the clinical judgement</b> of a healthcare provider and personal preference and circumstances. Any further additional doses should be administered at <b>least 8 weeks (2 months) after the last COVID-19 vaccine dose.</b>	

\* COVID-19 vaccination history refers to previous receipt of dose(s) of original monovalent (ancestral) mRNA, bivalent mRNA vaccine, Updated (2023–2024 Formula), or a combination of the three, unless otherwise specified.

† People who are recommended to receive a multidose mRNA series for initial vaccination (i.e., children ages 6 months–4 years and people who are moderately or severely immunocompromised) should receive all doses from the same manufacturer. However, in the following exceptional situations a different age-appropriate COVID-19 vaccine product may be administered: the same vaccine is not available, the person would otherwise not complete the vaccination series, or the person starts but is unable to complete a vaccination series with the same vaccine due to a contraindication.